The clinical spectrum of ocular allergy.
Ocular allergy is a very common pathology, and its incidence has increased in industrial countries in combination with an increase in atopy. Many different clinical features characterize the ocular allergy, which can be seasonal, perennial, or chronic. Therefore, ocular allergy must be considered part of the allergic syndrome; perennial or seasonal keratoconjunctivitis appear to be directly related to allergic rhinitis manifestations and, less frequently, to asthma and eczema. The principal field of research in ocular allergy concerns therapeutic applications and new concepts of physiopathologic mechanisms needed to understand the most optimal treatment that can be delivered.
Brémond-Gignac
Dominique
D
Department of Ophthalmology, Robert Debré Hospital, 48, bd Serurier, 75019 Paris, France. dominique.bremond@rdb.ap-hop-paris.fr
D000287:Administration, Topical; D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000485:Allergens / Q000009:adverse effects; D018926:Anti-Allergic Agents / Q000627:therapeutic use; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D003233:Conjunctivitis, Allergic / Q000145:classification* / Q000175:diagnosis* / Q000188:drug therapy; D017449:Dermatitis, Allergic Contact / Q000175:diagnosis / Q000628:therapy; D006634:Histamine H1 Antagonists / Q000627:therapeutic use; D006801:Humans; D008407:Mast Cells / Q000187:drug effects; D014663:Nasal Decongestants / Q000627:therapeutic use; D009883:Ophthalmic Solutions / Q000627:therapeutic use
D000305:Adrenal Cortex Hormones; D000485:Allergens; D018926:Anti-Allergic Agents; D000893:Anti-Inflammatory Agents; D006634:Histamine H1 Antagonists; D014663:Nasal Decongestants; D009883:Ophthalmic Solutions